跳至主要内容
临床试验/NCT01374802
NCT01374802已完成1 期

Effect of Multiple Dosing With 240 mg QD BI 201335 on the Steady-state Pharmacokinetics of 800 mg QD Darunavir Coadministered With 100 mg QD Ritonavir (DRV/r) in Healthy Male and Female Volunteers (an Open-label, Multiple-dose, Single Group, Single Fixed Sequence Phase I Study)

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
14
试验地点
1
主要终点
AUCτ,ss of Darunavir

研究概览

简要总结

The objective of the current study is to investigate the effect of multiple oral daily doses of BI 201335 on the steady-state pharmacokinetics of darunavir co-administered with ritonavir.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

BI 201335

Experimental

capsule for oral administration

干预措施: BI 201335 (Drug)

Darunavir 400 mg

Experimental

tablet for oral administration

干预措施: Darunavir (Drug)

Ritonavir 100 mg

Experimental

tablet for oral administration

干预措施: Ritonavir (Drug)

结局指标

主要结局

AUCτ,ss of Darunavir

时间窗: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities

Cτ,ss of Darunavir

时间窗: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir

Cmax,ss of Darunavir

时间窗: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)

maximum measured concentration of the analyte in plasma at steady-state

次要结局

  • Tmax,ss of Darunavir(0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Effect of Multiple Dosing With BI 201335 on the... | 临床试验